Generation and brain delivery of anti-aggregating antibodies against β-amyloid plaques using phage display technology

  • B. Solomon
  • D. Frenkel
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 62)


Antibodies towards the N-terminal region of the (β-amyloid peptide bind to β-amyloid fibrils, leading to their disaggregation. We generated anti-aggregating (β-amyloid antibodies using filamentous phages displaying the only four amino acids EFRH found to be the main regulatory site for β-amyloid formation. In order to overcome the low permeability of the blood brain barrier for targeting ’anti-aggregating’ mAbs to the βA plaques in the brain, we applied antibody engineering methods to minimize the size of the mAbs while maintaining their biological activity. We found that single-chain antibodies displayed on the surface of the phage are capable of entering the central nervous system (CNS). The feasibility of these novel strategies for the production and targeting of anti-aggregating antibodies against [3-amyloid plaques to disease affected regions in the CNS may have clinical potential for treatment of Alzheimer’s disease.


Amyloid Peptide Filamentous Phage Phage Display Technology Molecular Microbiology Brain Delivery 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bastein N, Trudel M, Simard C (1997) Protective immune responses induced by the immunization of mice with recombinant bacteriophage displaying an epitope of the human respiratory syncytical virus. Virology 234: 118–122CrossRefGoogle Scholar
  2. Frenkel D, Balass M, Solomon B (1998) N-Terminal EFRH sequence of Alzheimer’s β-amyloid peptide represents the epitope of its anti-aggregation antibodies. J Neuroimmunol 88: 85–90PubMedCrossRefGoogle Scholar
  3. Frenkel D, Katz O, Solomon B (2000a) Immunization against Alzheimer’s (3-amyloid plaques via EFRH-phage administration. Proc Natl Acad Sci USA 97(21): 11455–11459CrossRefGoogle Scholar
  4. Frenkel D, Solomon B, Benhar I (2000b) Modulation of Alzheimer’s β-amyloid neurotoxicity by site-directed single-chain antibody. J Neuroimmunol 106(1–2): 23–31CrossRefGoogle Scholar
  5. Levine H III (1993) Thioflavine T interaction with synthetic Alzheimer’s disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2: 404–410PubMedCrossRefGoogle Scholar
  6. McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552–554PubMedCrossRefGoogle Scholar
  7. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, m Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740): 173–177PubMedCrossRefGoogle Scholar
  8. Sladowski D, Steer SJ, Clothier RH, Balls M (1993) An improved MTT assay. J Immunol Methods 157(1–2): 203–207PubMedCrossRefGoogle Scholar
  9. Solomon B, Koppel R, Hanan E, Katzav T (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer (3-amyloid peptide. Proc Natl Acad Sci USA 93:452–455PubMedCrossRefGoogle Scholar
  10. Solomon B, Koppel R, Frenkel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer (3-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94: 4109–4112PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • B. Solomon
    • 1
  • D. Frenkel
    • 1
  1. 1.Department of Molecular Microbiology and Biotechnology, Faculty of Life SciencesTel Aviv UniversityIsrael

Personalised recommendations